Zurich Cantonal Bank
LENZ

Zurich Cantonal Bank’s LENZ Therapeutics LENZ Stock Holding History

Zurich Cantonal Bank’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-267
Closed -$4.27K – 3435
2025
Q4 		$4.27K Buy
+267
New +$7.78K ﹤0.01% 2504

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Zurich Cantonal Bank's LENZ Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its LENZ Therapeutics (LENZ) stake by 100% in Q2 2026, selling an estimated $49.1K and leaving 5 shares worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #2539.

Zurich Cantonal Bank first reported a position in LENZ in Q1 2025 and has held it in 5 quarters since. The position peaked at $55.8K in Q1 2026. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Zurich Cantonal Bank held 5 shares of LENZ Therapeutics worth $28 as of Q2 2026.
  • Zurich Cantonal Bank sold 6,094 LENZ Therapeutics shares in Q2 2026, an estimated $49.1K.
  • LENZ Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2539 holding.
  • Zurich Cantonal Bank first reported a position in LENZ Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Zurich Cantonal Bank's LENZ Therapeutics position peaked at $55.8K in Q1 2026.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.